EA
AKRO

Emerald Advisers’s Akero Therapeutics AKRO Stock Holding History

Emerald Advisers’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-206,771
Closed -$9.82M – 248
2025
Q3 		$9.82M Sell
206,771
-84,921
-29% -$4.11M 0.31% 103
2025
Q2 		$15.6M Sell
291,692
-2,710
-0.9% -$123K 0.57% 70
2025
Q1 		$11.9M Sell
294,402
-225,712
-43% -$9.57M 0.54% 75
2024
Q4 		$14.5M Sell
520,114
-4,313
-0.8% -$131K 0.56% 70
2024
Q3 		$15M Buy
524,427
+9,175
+2% +$239K 0.58% 70
2024
Q2 		$12.1M Sell
515,252
-23,621
-4% -$505K 0.51% 72
2024
Q1 		$13.6M Buy
538,873
+399,183
+286% +$9.59M 0.55% 75
2023
Q4 		$3.26M Buy
+139,690
New +$2.75M 0.14% 121

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Emerald Advisers's AKRO Position: Q4 2025 in Review

Emerald Advisers sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 206,771 shares — an estimated $9.82M sold.

Emerald Advisers first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $15.6M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Emerald Advisers reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Emerald Advisers sold 206,771 Akero Therapeutics shares in Q4 2025, an estimated $9.82M.
  • Emerald Advisers first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
  • Emerald Advisers's Akero Therapeutics position peaked at $15.6M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Emerald Advisers's 13F filing for Q4 2025, filed 9 Feb 2026.